ICPO Theranostics Virtual Summit 2024

Radiotheranostics: New Era for Alpha Emitters and Radiopharmaceuticals

When:

14. November 2024: 2:00 pm – 7:00 pm (CET)

15. November 2024: 9:00 am – 03:00 pm (CET)

Registration possible until: 13.11.2024, 12:00 am (CET)

Where: online

Welcome to the IPCO Theranostics Virtual Summit 2024!

Dear ICPO Friends, Supporters and Valued Partners, 

Building on the growing success of the first edition of the ICPO Theranostics Summit in 2022, as well as of the multiple FAP sessions hosted during the ICPO Forum in 2023 and the Theranostics World Congress earlier in 2024, the ICPO Foundation is pleased to launch its ICPO Theranostics Summit 2024 next November 14 & 15 as all virtual event.

This year, our ICPO Theranostics Summit will feature a world-class scientific program powered by distinguished academic and industry experts from the ICPO Community. Our focus will be to explore innovations, from bench to bedside, first in the field of alpha emitters, with actinium and more, then across the range of new radiopharmaceuticals, such as FAP and beyond. Moreover, our objective will be to sketch together the contours of a new era in cancer care, ultimately benefiting to patients around the globe.

Whether you are very familiar with alpha emitters and new radiopharmaceuticals already or just curious as to how these latest developments will potentially impact clinical applications in your country, the ICPO Theranostics Summit 2024 will be insightful for you. It will allow you to follow eye-opening talks and vibrant panel discussions while also raising your own questions.

We will be delighted to count you in and to foster together an essential critical debate around today’s and tomorrow’s clinical relevance of radiotheranostics in the perspective of improved patient outcomes and better access to more personalized, abundant and democratized cancer care.

To join us, please register below via the orange tab.

Sincerely,

Sen. HC Udo J. Vetter
Chairman of the ICPO Board of Trustees

Prof. Dr. Richard P. Baum, MD
Trustee of the ICPO Foundation and Scientific Co-Chair of the ICPO Theranostics Summit 2024

Prof. Dr. Frederik Giesel, MD
Scientific Chair of the ICPO Theranostics Summit 2024

Odile Jaume
CEO of the ICPO Foundation

Preliminary Scientific Program

Version July 10, 2024

Day 1: November 14, 2024 (02:00 pm - 07:30 pm (CET)

Alpha Emitters with focus on Ac225, At211 and Pb212 // Latest innovation and clinical establishment today // Patient access and global perspective.

02:00 - 02:20
02:20 - 02:40
02:40 - 03:25
03:25 - 04:25
04:35 - 04:35
04:35 - 05:20
05:20 - 06:35
06:35 - 07:20
07:20 - 07:30
Program
Welcome
KEYNOTE: History of Alpha Therapy - S. Larson (USA)
SESSION I: Alpha Emitters 101
- Radiobiology need to know about Alphas - J-P. Pouget (France)
- Dosimetry techniques for alpha radioligand therapy: where are we now? - P. Fragoso Costa (Germany)
- Radiochemistry Alpha specificities and latest advances - M. Nader (Germany
SESSION II: Alpha Emitters from Bench to Bed Side
- Ac225 Clinical Insights from WARMTH Act LANCET Oncology Study - M.Sathekge (South Africa)
- At211 from preclinical to the clinic - T. Watabe (Japan)
- Pb212 Preclinical Experience and Clinical Potential - N. Pullen (Switzerland)
- Pb212 PSMA Clinical experience in prostate cancer and isotope considerations for novel targets, binders and indications” A. Karmann (USA)
BREAK
SESSION III: Alpha Emitters beyond PSMA
- Innovation in Ac225 Supply - TBC
- Next-generation SSTR2 targeting in Small Cell Lung Cancer with Ac-225 - G. Gericke (Germany)
- Pb212 Dotamate in NET - E. Delpassand (USA)
SESSION IV: Challenges of Alpha therapies versus conventional emitters
- Global supply status and challenges of Ac225 and other alphas - N.Quigley (Germany)
- At211 the European Network - J-F Gestin (France)
- Pb212 Generators: Different Concepts & Logistics - M. Schultz (USA)
- Regulatory Perspective on the Introduction of Alpha Therapies - TBC
- Ethics in Clinical trials of Alpha Therapies - J. Mailman (USA)
PANEL: Global perspective on patient access today and in 5 years
Moderators: R.P. Baum and F. Giesel (Germany)
Wrap up and Closing of Day 1

Day 2: November 15, 2024 (09:00 am - 03:00 pm (CET)

Radiopharmaceuticals with focus on FAP, CA9, CXCR4 and GPC3 // From trials to clinical profiles // Patient access and global perspective

09:00 - 09:10
09:10 - 09:30
09:30 - 10:45
10:45 - 11:30
11:30 - 11:50
11:50 - 12:00
12:00 - 12:45
12:45 - 01:45
01:45 - 02:05
02:05 - 02:50
02:50 - 03:00
Program
Welcome
KEYNOTE: History of FAP till today - A. Scott (Australia)
SESSION V: FAP Diagnostics in Oncology and non-Oncology
- FAP Dx into clinical practice today – malignant and non-malignant - F. Giesel (Germany)
- Myocardiac and Organ Fibrosis - TBC
- FAP Dx Some On-going Clinical Trials - S. Mosessian (USA)
SESSION VI: FAP Therapy
- FAP Peptide Targeted Tx - R.P. Baum (Germany)
- FAP Dimer - S. Ballal (India)
- Optimisation of FAP ligands for therapy through multimerization and medicinal chemistry approaches - Jacqueline Mock (Switzerland)
PANEL 2: FAP as Imaging Biomarker
Moderator: E. Zan (USA)
BREAK
SESSION VII: CA9
- G250 Antibody Renal Cell Cancer - S.T. Lee (Australia)
- CA9 Theranostics with Small Molecules - M. Hofman (Australia)
- CA9 Some On-going Clinical Trials - David Cade and Stuart Gribble (Australia)
SESSION VIII: CXCR4 and GPC3
- CXCR4 Hematological Indications - R. Werner (Germany)
- CXCR4 some On-going Clinical Trials - H. Bouterfa (Germany)
- GPC3 Promise for Oncology - W. Weber (Germany)
- GPC1 Promise for Oncology - S. Serada (Japan)
PANEL 3: Antibody Drug Conjugates contra Radiopharmaceutical Therapies?
Moderator: K. Herrmann (Germany)
FINAL ROUND TABLE: A new theranostics era for patients, fueled by innovation & regulatory advances
Wrap up and Closing of Summit 2024

Sponsors

The ICPO Virtual Theranostics Summit 2024 is supported by a large number of renowned sponsors who make significant contributions to the realization and success of this event.

These sponsors come from various fields of medicine, technology and venture capital and share a common vision: the advancement of radiotheranostics research and application.

The ICPO Virtual Theranostics Summit 2024 will be a significant forum for scientists, researchers and professionals from around the world to collaboratively shape the future of Radiomolecular Precision Oncology.

Are you interested in sponsoring this event?

Please contact us directly to get an overview of the different sponsoring packages we can offer you.

icpo.summit.2024@kisconcept.agency

Supporters

Media Partners

Invited Speakers

Frederik Giesel

Ecin Zan

Richard P. Baum

Frank Rösch

Ken Herrmann

Cristina Mueller

Andrew Scott

Sherly Mosessian

Sanjana Ballal

Germo Gericke

Wolfgang Weber

Michael Nader

Anna Karmann

Satoshi Serada

The ICPO Foundation

The ICPO Foundation is establishing an international collaborative network of certified ICPO Centers by sharing knowledge, standards and education in Radiomolecular Precision Oncology. World-class standardized education of healthcare professionals is key to ensure sustainable patient access at a global scale. Therefore, the ICPO Foundation launched the ICPO Academy for Theranostics.

The goals of the ICPO Foundation:

Scaling global patient access to Radiomolecular Precision Oncology

Supporting theranostics education and research

Building the ICPO Collaborating Centers network

Creating a collaborative theranostics community

Host
Organizer

Questions? Mails us!